Percutaneous Tissue-Engineered Pulmonary Valved Stent Implantation Georg Lutter, MD, PhD, Anja Metzner, PhD, Thomas Jahnke, MD, PhD, René Bombien, MD, Jessica Boldt, MS, Kenji Iino, MD, Jochen Cremer, MD, PhD, Ulrich A. Stock, MD, PhD The Annals of Thoracic Surgery Volume 89, Issue 1, Pages 259-263 (January 2010) DOI: 10.1016/j.athoracsur.2009.06.048 Copyright © 2010 The Society of Thoracic Surgeons Terms and Conditions
Fig 1 Correct positioning of a tissue-engineered autologous valved stent in the pulmonary position in an ovine model (A) at the time of implantation and (B) at the 4-week follow-up. The Annals of Thoracic Surgery 2010 89, 259-263DOI: (10.1016/j.athoracsur.2009.06.048) Copyright © 2010 The Society of Thoracic Surgeons Terms and Conditions
Fig 2 (A, B) Gross morphology of tissue-engineered pulmonary valved stent. The Annals of Thoracic Surgery 2010 89, 259-263DOI: (10.1016/j.athoracsur.2009.06.048) Copyright © 2010 The Society of Thoracic Surgeons Terms and Conditions
Fig 3 (A) Hematoxylin and eosin staining (original magnification ×200) and (B) Russel-Movat's pentachrome staining (original magnification ×200) of tissue-engineered heart valve 4 weeks after implantation (bar represents 100 μm). The Annals of Thoracic Surgery 2010 89, 259-263DOI: (10.1016/j.athoracsur.2009.06.048) Copyright © 2010 The Society of Thoracic Surgeons Terms and Conditions
Fig 4 (A) Endothelial staining with platelet/endothelial cell adhesion molecule-1 (original magnification ×200; bar represents 100 μm) and (B) Immunofluorescence von-Willebrand-Factor staining (original magnification ×200; bar represents 100 μm). The Annals of Thoracic Surgery 2010 89, 259-263DOI: (10.1016/j.athoracsur.2009.06.048) Copyright © 2010 The Society of Thoracic Surgeons Terms and Conditions
Fig 5 α-actin-staining (original magnification ×200; bar represents 100 μm). The Annals of Thoracic Surgery 2010 89, 259-263DOI: (10.1016/j.athoracsur.2009.06.048) Copyright © 2010 The Society of Thoracic Surgeons Terms and Conditions